GNLX supply chain intelligence for Genelux Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Genelux Corporation (GNLX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | The Company may, from time to time, offer and sell shares of the Company's common stock, par value $0.001 per share (the 'Placement Shares'), having an aggregate offering price of up to $100,000,000,… |
| NEWSOARA-BIOPHARMA-CO-LTD | NEWSOARA-BIOPHARMA-CO-LTD | 90% | In September 2021, the Company entered into the Newsoara License Agreement with Newsoara BioPharma Co. Ltd. |
| NEWSOARA-HYK-BIOPHARMACEUTICALS-CO-LTD | NEWSOARA-HYK-BIOPHARMACEUTICALS-CO-LTD | 90% | In October 2025, Newsoara BioPharma Co. Ltd. assigned all of its rights and obligations under the Newsoara License Agreement to an affiliate, Newsoara HYK Biopharmaceuticals Co., Ltd. |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers a… |
| BMY | Bristol-Myers Squibb Company | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| CADL | Candel Therapeutics, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| CADL | Candel Therapeutics, Inc. | 72% | Reciprocal relationship from CADL graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from CADL graph: Reciprocal relationship from GNLX graph: ials between batches from a single … |
| CELG-RI | CELG-RI | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. … |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our dru… |
| JNJ | Johnson & Johnson | 72% | d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for on… |
| LLY | Eli Lilly and Company | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: ials between batches from a single su… |
| ONCY | Oncolytics Biotech Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| ONCY | Oncolytics Biotech Inc. | 72% | Reciprocal relationship from ONCY graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| REPL | Replimune Group, Inc. | 72% | Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The… |
| REPL | Replimune Group, Inc. | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| TOVX | Theriva Biologics, Inc. | 72% | Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| TOVX | Theriva Biologics, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate … |
| BMYMP | Bristol-Myers Squibb Co | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| CADL | Candel Therapeutics, Inc. | 72% | Reciprocal relationship from CADL graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pr… |
| CADL | Candel Therapeutics, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| CELG-RI | CELG-RI | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from … |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from IOVA g… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| JNJ | Johnson & Johnson | 72% | d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for on… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our dru… |
| LLY | Eli Lilly and Company | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pro… |
| ONCY | Oncolytics Biotech Inc. | 72% | Reciprocal relationship from ONCY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from ONCY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from ONCY g… |
| ONCY | Oncolytics Biotech Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REGN g… |
| REPL | Replimune Group, Inc. | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| REPL | Replimune Group, Inc. | 72% | Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing f… |
| TOVX | Theriva Biologics, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| TOVX | Theriva Biologics, Inc. | 72% | Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from TOVX g… |
| NEWSOARA-HYK-BIOPHARMACEUTICALS-CO-LTD | NEWSOARA-HYK-BIOPHARMACEUTICALS-CO-LTD | 62% | g expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug sup… |
| USA-LLC | USA-LLC | 62% | g expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug sup… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GNLX-DEBT-9831 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| GNLX-DEBT | Debt stack $900,000 | 90% | Market cache reports total debt of $900,000. |
| GNLX-DEBT-9830 | Warrants outstanding: 7500000 | 90% | xbrl warrant detail from xbrl 2024-09-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GNLX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 71 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| TOVX | Theriva Biologics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| CADL | Candel Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ONCY | Oncolytics Biotech Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| IOVA | Iovance Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['customer', 'supplier'] |
| CRBU | Caribou Biosciences, Inc. | 50.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 50.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| AORT | Artivion, Inc. | 50.00 | 2 | |
| CVRX | CVRx, Inc. | 50.00 | 2 | |
| CHKP | Check Point Software Technologies Ltd. | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 50.00 | 2 |